Spironolactone
- Generic Name
- Spironolactone
- Brand Names
- Aldactazide, Aldactone, Carospir, Qaialdo
- Drug Type
- Small Molecule
- Chemical Formula
- C24H32O4S
- CAS Number
- 52-01-7
- Unique Ingredient Identifier
- 27O7W4T232
- Background
Spironolactone is a potassium-sparing diuretic. It binds to mineralocorticoid receptors and functions as aldosterone antagonists. It promotes sodium and water excretion and potassium retention. Spironolactone was originally developed purely for this ability before other pharmacodynamic properties of the drug were discovered. It is indicated to treat several conditions, including heart failure, edema, hyperaldosteronism, and hypertension. Off-label uses of spironolactone include hirsutism, female pattern hair loss, and adult acne vulgaris.
Spironolactone was developed in 1957, marketed in 1959, and approved by the FDA on January 21, 1960.
- Indication
Spironolactone is indicated for the treatment of the following conditions:
As spironolactone has antiandrogenic activity, its off-label uses include the treatment of hirsutism, female pattern hair loss, and adult acne vulgaris.
- Associated Conditions
- Edema, Hypertension, Primary Aldosteronism, Primary Hyperaldosteronism, Secondary hyperaldosteronism, Chronic heart failure with reduced ejection fraction (NYHA Class III), Chronic heart failure with reduced ejection fraction (NYHA Class IV), Idiopathic hyperaldosteronism, Refractory Edema
- Associated Therapies
- Perioperative drug treatment, Maintenance therapy
Mineralocorticoid Receptor in the Treatment of Severe Depression
- Conditions
- Major Depression
- First Posted Date
- 2006-02-23
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- Universitätsklinikum Hamburg-Eppendorf
- Target Recruit Count
- 65
- Registration Number
- NCT00295347
- Locations
- 🇩🇪
University Hospital Hamburg-Eppendorf, Hamburg, Germany
Is Spironolactone Safe and Effective in the Treatment of Cardiovascular Disease in Mild Chronic Renal Failure?
- Conditions
- Chronic Kidney DiseaseCardiovascular Disease
- Interventions
- Drug: SpironolactoneDrug: Placebo
- First Posted Date
- 2006-02-14
- Last Posted Date
- 2008-05-21
- Lead Sponsor
- University Hospital Birmingham
- Target Recruit Count
- 120
- Registration Number
- NCT00291720
- Locations
- 🇬🇧
University Hospital Birmingham, Birmingham, West Midlands, United Kingdom
Spironolactone to Decrease Potassium Wasting in Hypercalciurics on Thiazides Diuretics
- Conditions
- Idiopathic HypercalciuriaHypokalemia Caused by Thiazide Diuretics
- First Posted Date
- 2006-01-13
- Last Posted Date
- 2009-12-03
- Lead Sponsor
- Indiana University School of Medicine
- Target Recruit Count
- 10
- Registration Number
- NCT00276289
- Locations
- 🇺🇸
Indiana University Department of Medicine, Division of Nephrology, Indianapolis, Indiana, United States
Clinical Trial Studying the Effects of Spironolactone on Heart and Skeletal Muscle Function in Chronic Alcoholics
- First Posted Date
- 2005-09-26
- Last Posted Date
- 2010-10-20
- Lead Sponsor
- University of Aarhus
- Target Recruit Count
- 40
- Registration Number
- NCT00226109
- Locations
- 🇩🇰
Department of Medicine V (gastroenterology and hepatology), Aarhus, Denmark
Impact of Medical and Surgical Therapy on Functional Mitral Regurgitation
- Conditions
- Heart DiseasesCardiovascular DiseasesCoronary Disease
- First Posted Date
- 2005-09-23
- Last Posted Date
- 2014-02-19
- Lead Sponsor
- Baylor Research Institute
- Target Recruit Count
- 250
- Registration Number
- NCT00224809
- Locations
- 🇺🇸
Baylor Research Institute, Dallas, Texas, United States
Novel Treatment for Diastolic Heart Failure in Women
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2013-02-18
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 48
- Registration Number
- NCT00206232
- Locations
- 🇺🇸
Baylor College of Medicine Heart Clinic, Houston, Texas, United States
Efficacy of Therapy With the Spironolactone Pills Compared to Minoxidil Lotion in Female Pattern Hair Loss
- Conditions
- Female Pattern Hair Loss
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- University of British Columbia
- Target Recruit Count
- 40
- Registration Number
- NCT00175617
- Locations
- 🇨🇦
UBC Division of Dermatology, Hair Research and Treatment Centre, Vancouver, British Columbia, Canada
Renin-angiotensin-aldosterone System (RAAS), Inflammation, and Post-Operative Atrial Fibrillation (AF)
- Conditions
- Atrial Fibrillation
- Interventions
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2013-03-22
- Lead Sponsor
- Vanderbilt University
- Target Recruit Count
- 455
- Registration Number
- NCT00141778
- Locations
- 🇺🇸
Vanderbilt University, Nashville, Tennessee, United States
Larger Dose of Spironolactone for the Treatment of Patients With Nonischemic Cardiomyopathy
- Conditions
- Heart Failure, Congestive
- First Posted Date
- 2005-08-01
- Last Posted Date
- 2009-07-15
- Lead Sponsor
- Hebei Medical University
- Target Recruit Count
- 200
- Registration Number
- NCT00125437
- Locations
- 🇨🇳
The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
PIE II: Pharmacological Intervention in the Elderly II
- Conditions
- Heart Failure, CongestiveDiastolic Heart Failure
- Interventions
- Drug: PlaceboDrug: Spironolactone
- First Posted Date
- 2005-07-26
- Last Posted Date
- 2019-02-27
- Lead Sponsor
- Wake Forest University
- Target Recruit Count
- 80
- Registration Number
- NCT00123955
- Locations
- 🇺🇸
Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.